(389) Week-long normoglycaemia in diabetic mice and pigs via a dose of glucose-responsive insulin complex

Over 20% of diabetics require insulin therapy to maintain normal blood glucose. The treatment is burdensome due to daily multiple subcutaneous injections. Additionally, it carries risks of frequent hyper- and hypoglycemia day and night. PBA-based glucose-responsive carriers exhibit rapid, robust in vitro/vivo insulin release, mimicking β-cell function by dynamically releasing insulin in response to blood glucose. However, it remains a challenge to regulate blood glucose levels for longer than one week after a single dose.